SPORE in Prostate Cancer

项目摘要 在过去的15年里，斯隆·凯特琳癌症纪念馆前列腺癌中的孢子 该中心在前列腺癌研究和治疗方面取得了重大进展，使用 进化对肿瘤生长驱动因素的机制理解以改善患者状况 在疾病的临床范围内进行管理。应用适应风险的方法， 是基于生物标记物的，我们的工作导致了新的诊断血液测试的发展和 区分惰性癌症和临床重大癌症的预后模型，新发现 治疗靶点，它们在临床前模型中的验证，以及成功开发 根据前列腺局的建议设计的试验中针对他们的药物 癌症工作组。我们的努力已经影响了世界各地的临床实践。 由最先进的分子图谱和生物信息学相结合的最新发现 由研究界承诺获得代表人类前列腺癌的 所有临床状态的分析，正在迅速导致基于生物学的分类法，这将进一步 完善医疗决策--个性化、精准医疗。在接下来的5年里，我们 该计划将继续侧重于确定导致疾病的机制 进展和治疗耐药性，开发有效的分析方法来确定患者的情况 可用于临床环境的肿瘤，设计专门的生物标记物试验以验证 他们在临床上，并展示了他们的效用，为医疗决策提供信息。我们是 相信我们的努力不仅将改善患者的预后，而且将使迫切需要的 新的系统疗法将以更快的速度成功开发。我们的孢子是有组织的 纳入5个紧密结合的重大研究项目，以实现总体目标。每个人 由一名基础和一名临床研究员领导，他们领导着一个多学科团队， 选择它是因为其出色的翻译潜力和处理危重未满足患者的能力 需要。这种“团队科学”的方法超越了我们计划的范围，包括 与其他机构和网络、联邦机构和行业的重要合作，包括 其他孢子和转化科学项目，国防部变革性 Impact奖，汇集了来自5个前列腺的病理学家和临床肿瘤学家 孢子用于分析性验证基于组织的预测性生物标记物分析，以及前列腺 癌症临床试验联盟，它实际上保证了重要的基础和临床 通过我们的孢子和我们的研究网络做出和发展的发现是 转换为快速、高效地到达人类终端。

Project Summary Over the past 15 years, the SPORE in Prostate Cancer at Memorial Sloan Kettering Cancer Center has made significant advances in prostate cancer research and treatment, using the evolving mechanistic understanding of the drivers of tumor growth to improve patient management across the clinical spectrum of the disease. Applying a risk-adapted approach that is biomarker based, our work has led to the development of new diagnostic blood tests and prognostic models to distinguish indolent from clinically significant cancers, the discovery of new therapeutic targets, their validation in preclinical models, and the successful development of drugs directed to them in trials designed according to the recommendations of the Prostate Cancer Working Group. Our efforts have impacted clinical practice worldwide. Recent discoveries enabled by state-of-the-art molecular profiling and bioinformatics, combined with a commitment by the research community to obtain human prostate cancers representing all clinical states for analysis, are leading rapidly to a biology-based taxonomy that will further refine medical decision making—personalized, precision medicine. Over the next 5 years, our program will continue to focus on defining the mechanisms that contribute to disease progression and resistance to therapy, developing validated assays to identify them in patient tumors that can be used in a clinical setting, designing dedicated biomarker trials to validate them clinically, and demonstrating their utility to inform medical decision making. We are confident that our efforts will not only improve patient outcomes but will enable urgently needed new systemic therapies to be successfully developed more rapidly. Our SPORE is organized into 5 major research projects that are tightly integrated to achieve the overall objectives. Each is headed by a basic and a clinical investigator who lead a multidisciplinary team that was chosen for its outstanding translational potential and ability to address critical unmet patient needs. This “team science” approach extends beyond the boundaries of our program to include vital collaborations with other institutions and networks, federal agencies, and industry, including other SPOREs and translational science programs, the Department of Defense Transformative Impact Award, which brings together pathologists and clinical oncologists from 5 prostate SPOREs to analytically validate tissue based predictive biomarker assays, and the Prostate Cancer Clinical Trials Consortium, which virtually guarantees that important basic and clinical discoveries made and developed through our SPORE and in our research network are translated to reach human endpoints quickly and efficiently.